| Wonsick Choe, | |
|
115 N Colonial Dr, Harrington Park, NJ 07640-1063 | |
| (718) 594-5868 | |
| Not Available |
| Full Name | Wonsick Choe |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Experience | 27 Years |
| Location | 115 N Colonial Dr, Harrington Park, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689070690 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | C42362 (California) | Secondary |
| 207U00000X | Nuclear Medicine | C42362 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Oroville Hospital | Oroville, CA | Hospital |
| Adventist Health And Rideout | Marysville, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ampla Health | 5092619270 | 63 |
News Archive
The research, conducted by Wilma Koutstaal (University of Minnesota) and Alaitz Aizpurua (UPV/EHU), concludes that the memory of older adults is not as deficient as has been thought until now. Elderly people remember fewer specific details than younger people and, in general, both groups retain concrete information about events experienced better than abstract information. The main difference is to be found in the capacity to remember more distant facts: youngsters remember them better.
Valeant Pharmaceuticals International announced today that it has priced its previously announced offering of senior unsecured notes, which consists of $500 million of 6.75% Senior Notes due 2017 and $700 million of 7.00% Senior Notes due 2020 (collectively, the "Notes"). The $1.2 billion combined aggregate principal amount of the Notes was increased from the previously announced offering size of $1.0 billion. The offering is expected to close on or about September 28, 2010.
Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has renegotiated the terms of its commercial partnership with Meda for Xerese, its unique marketed product for cold sores (herpes labialis).
› Verified 9 days ago
| Entity Name | Ampla Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952333635 PECOS PAC ID: 5092619270 Enrollment ID: O20040225001116 |
News Archive
The research, conducted by Wilma Koutstaal (University of Minnesota) and Alaitz Aizpurua (UPV/EHU), concludes that the memory of older adults is not as deficient as has been thought until now. Elderly people remember fewer specific details than younger people and, in general, both groups retain concrete information about events experienced better than abstract information. The main difference is to be found in the capacity to remember more distant facts: youngsters remember them better.
Valeant Pharmaceuticals International announced today that it has priced its previously announced offering of senior unsecured notes, which consists of $500 million of 6.75% Senior Notes due 2017 and $700 million of 7.00% Senior Notes due 2020 (collectively, the "Notes"). The $1.2 billion combined aggregate principal amount of the Notes was increased from the previously announced offering size of $1.0 billion. The offering is expected to close on or about September 28, 2010.
Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has renegotiated the terms of its commercial partnership with Meda for Xerese, its unique marketed product for cold sores (herpes labialis).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Wonsick Choe, 115 N Colonial Dr, Harrington Park, NJ 07640-1063 Ph: (718) 594-5868 | Wonsick Choe, 115 N Colonial Dr, Harrington Park, NJ 07640-1063 Ph: (718) 594-5868 |
News Archive
The research, conducted by Wilma Koutstaal (University of Minnesota) and Alaitz Aizpurua (UPV/EHU), concludes that the memory of older adults is not as deficient as has been thought until now. Elderly people remember fewer specific details than younger people and, in general, both groups retain concrete information about events experienced better than abstract information. The main difference is to be found in the capacity to remember more distant facts: youngsters remember them better.
Valeant Pharmaceuticals International announced today that it has priced its previously announced offering of senior unsecured notes, which consists of $500 million of 6.75% Senior Notes due 2017 and $700 million of 7.00% Senior Notes due 2020 (collectively, the "Notes"). The $1.2 billion combined aggregate principal amount of the Notes was increased from the previously announced offering size of $1.0 billion. The offering is expected to close on or about September 28, 2010.
Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has renegotiated the terms of its commercial partnership with Meda for Xerese, its unique marketed product for cold sores (herpes labialis).
› Verified 9 days ago